This causes the uninfected memory CD4+ T cell population to increase during anti-CCR5 therapy, yielding a drop in an/am and hindering a potential switch to X4 as well as immunodeficiency (Figure 2C, small kM4 regime). This evidence concerns the gene CD4 and immunodeficiency disease.